Search by Ticker
Resverlogix Corp. (TSX:RVX)
The following stock analysis is based on 7.5 years of data (i.e. since Feb 22, 2013). All the stock history has been downloaded.
Resverlogix Corp. trades on the Toronto exchange in CAD dollars.
It is in the sector.
It is currently trading at $0.77 ($0.76 the previous day).
The current Canada / US exchange rate is 1.33743.
The year over year average increase is -16.3% per year assuming steady exponential growth. The actual 5 year average is 15.06. Details on the individual increase in one year intervals is provided below.
|Past Performance||Average Price||Percent Change|
|1 year||1.7565217391304||-46.3||- Below Average|
|2 year||3.2732258064516||89.6||+ Above Average|
|3 year||1.7263445378151||-4.4||- Below Average|
|4 year||1.8059183673469||20.9||+ Above Average|
|5 year||1.4931297709924||15.5||+ Above Average|
The worst drop it has had in recent years is -93.9%. It has a shape to the stock curve, which means
Resverlogix Announces Publication on Apabetalone in Cardiovascular TherapeuticsTue, 04 Aug 2020 12:00:00 COVID-19 Preclinical Work ContinuesCALGARY, Alberta, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. (and"Resverlogixand" or the and"Companyand") (TSX:RVX) is pleased to announce today the recent publication of an article titled: “Epigenetic modulation by apabetalone counters cytokine driven acute phase ...... Read Full Article
Resverlogix Announces Extension of its Filing Calendar Based on Continuous Disclosure ExemptionTue, 28 Jul 2020 22:00:00 CALGARY, Alberta, July 28, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. (and"Resverlogixand" or the and"Companyand") (TSX:RVX) announces that it intends to rely on blanket exemptions issued by provincial securities commissions due to the COVID-19 outbreak that permit the Company to ...... Read Full Article
Resverlogix Secures One-Year Extension of Maturity Date of DebentureWed, 22 Jul 2020 11:00:00 CALGARY, Alberta, July 22, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. (and"Resverlogixand" or the and"Companyand") (TSX:RVX) announced today that it has closed a one-year extension of the maturity date of its debenture. Mr. Donald McCaffrey, President and CEO stated, and"...... Read Full Article
The Market’s Major Volatility Indexes Are Signaling a Replay of March’s DeclineThu, 25 Jun 2020 21:06:00 Is the stock market setting up for a replay of the March decline? Given the action of various measures of volatility, we must at least prepare for that likelihood.... Read Full Article
Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling StudyMon, 22 Jun 2020 11:00:10 Resverlogix Corp. ("Resverlogix") (RVX.TO) is pleased to announce that the U.S. Food and Drug Administration (FDA) has accepted its BETonMACE2 clinical plan as a registration enabling study with positive implications for Resverlogix and its ongoing partnership discussions. The ...... Read Full Article
Zenith Announces Corporate Update Conference Call and Webcast on June 18, 2020 and US$5 Million Equity InvestmentTue, 16 Jun 2020 11:00:10 Zenith Capital Corp. (“Zenith” or the “Company”) today announces it will be hosting a corporate update via conference call and webcast on Thursday, June 18, 2020 at 9:00 am MT / 11:00 am ET. Zenith has completed the issuance of 1,333,334 common shares to the Subscriber ...... Read Full Article
Resverlogix Announces Key BETonMACE Renal Data from Plenary Session Presentation at ERA-EDTA Virtual CongressTue, 09 Jun 2020 12:30:10 Resverlogix Corp. ("Resverlogix") (RVX.TO) is pleased to announce key data from its BETonMACE clinical trial in pre-specified stage 3 chronic kidney disease (CKD) patients. This data was presented in a virtual oral plenary session at the 57th ERA-EDTA Virtual Congress ...... Read Full Article
Resverlogix Plans COVID-19 Clinical Trial Program LaunchMon, 01 Jun 2020 12:30:10 CALGARY, Alberta, June 01, 2020 -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that it is moving forward with a plan to further evaluate.... Read Full Article
Zenith Epigenetics: ZEN-3694: Resistance is FutileMon, 04 May 2020 09:55:00 Zenith Epigenetics offers a differentiated approach to bromodomain extra terminal (BET) inhibition. The company’s lead candidate, ZEN-3694, has demonstrated a synergistic ability to resensitize the tumor environment to approved therapies in clinical trials with enzalutamide and talazoparib.... Read Full Article
Resverlogix Announces Participation at the American College of Cardiology Scientific Sessions together with the World Congress of Cardiology VirtualTue, 31 Mar 2020 12:00:10 BETonMACE shows apabetalone treatment was associated with 41% reduction in hospitalizations for heart failure in patients with type 2 diabetes and recent Acute Coronary Syndrome.... Read Full Article
Resverlogix Announces Publication of Key Apabetalone Study BETonMACE in the Journal of the American Medical AssociationMon, 30 Mar 2020 12:00:10 Resverlogix Corp. ("Resverlogix" or the "Company") (RVX.TO) announced today the recent publication of an article titled: “Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes,” in ...... Read Full Article
Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent PublicationTue, 24 Mar 2020 12:00:10 CALGARY, Alberta, March 24, 2020 -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce a March 23, 2020 bioRxiv publication that has shown.... Read Full Article
Resverlogix Invites Collaborations for use of Apabetalone in Trials and Studies to Combat the Spread of COVID-19 Based on New ResearchMon, 23 Mar 2020 11:00:10 Resverlogix Corp. (“Resverlogix”) (RVX.TO) announces that it is seeking to collaborate with organizations currently testing therapies for SARS-CoV-2 (the virus responsible for COVID-19) in pre-clinical or clinical models. Apabetalone prevents specialized proteins – called bromodomain and extraterminal domain (BET) proteins – ...... Read Full Article
Resverlogix Receives US FDA Breakthrough Therapy Designation for ApabetaloneMon, 03 Feb 2020 12:30:10 Resverlogix Corp. (“Resverlogix” or the "Company") (RVX.TO) is pleased to announce the U.S. Food and Drug Administration (“FDA”) has granted Breakthrough Therapy Designation for apabetalone in combination with top standard of care, including high-intensity statins, for the secondary ...... Read Full Article
Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVDMon, 13 Jan 2020 13:18:12 CALGARY, Alberta, Jan. 13, 2020 -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) is pleased to announce today additional highly significant findings and clear.... Read Full Article
Resverlogix Appoints Dicky To to its Board of DirectorsFri, 20 Dec 2019 13:30:10 Resverlogix Corp. (“Resverlogix” or the "Company") (RVX.TO) today announced that Mr. Dicky To has been appointed to the Company’s Board of Directors. Dicky is a partner of ORI Capital and has over 25 years of experience in structure, transaction ...... Read Full Article
Zenith Epigenetics Announces Clinical Advancement of ZEN-3694Thu, 19 Dec 2019 13:58:42 Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the significant clinical advances of ZEN-3694, the Company’s lead compound being developed for epigenetic combination therapies in oncology. “I am very pleased to report these significant advances in our ZEN-3694 ...... Read Full Article
Resverlogix Announces Change to its Board of DirectorsWed, 11 Dec 2019 13:30:10 Resverlogix Corp. (“Resverlogix” or the "Company") (RVX.TO) today announced that Dr. Eldon Smith has stepped down from the Board of Directors, effective today. “We would like to thank Eldon for his many years of service and wish him all ...... Read Full Article
Reminder: Resverlogix to Hold Conference Call and Webcast on December 6th, 2019Thu, 05 Dec 2019 23:00:10 CALGARY, Alberta, Dec. 05, 2019 -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) reminds stakeholders that the Company will hold a conference call and webcast.... Read Full Article
Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019Mon, 02 Dec 2019 13:30:10 Apabetalone treatment improves cognition in CVD patients with diabetes Subsequent conference call and webcast scheduled to present BETonMACE prespecified cognition assessment.... Read Full Article